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Vagus nerve stimulation (VNS) therapy is approved in the
United States by the FDA in 1997 for medically refractory partial
epilepsy in patients of ages 12 years and above. The most common
stimulation-associated side effects are voice alteration, hoarse-
ness, throat and neck pain, headache, cough, and dyspnea. Four
patients with VNS had late-onset bradycardia and asystole,
attributed to VNS stimulation. Their ages were 13, 17, 47, and
55. Cardiac symptoms were noted after 2.33–9 years post-
implantation [1–4]. Three cases had symptoms correlated with
stimulation, monitored by electrocardiogram [1,2,4]. This new
case report highlights cardiac syncope with very similar clinical
presentation as previous four cases, and raises the concern for
cardiac symptoms, even many years after VNS implantation.
2. Case report
A 56-year-old man with medically refractory partial epilepsy
and anxiety, started having partial seizures, associated with
staring, lips turning blue, and hands wringing, at age nine. He
started having partial seizures, associated with staring, lips turning
blue, and hands wringing, at age nine. He started having several
secondary convulsions at age 16. After failing numerous anti-
epileptic drugs (AEDs) and ruling out epilepsy surgery therapy,
VNS was implanted at age 42. It had completely eliminated
seizures with secondary convulsion, and signiﬁcantly decreased* Tel.: +1 405 271 4113; fax: +1 405 271 5723.
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month. He underwent pulse generator replacement with VNS
model 104 at age 54. Routine intraoperative lead testing result is
unknown. After 1 year and 11 months post-implantation, he
experienced recurrent syncope, associated with lightheadedness,
difﬁculty breathing, and complete loss of consciousness, lasting up
to 10 s. He had no postictal confusion. His stimulation parameters
(21 s on-time, 3.2 min off-time, 2.75 mA output current, 25 Hz
signal frequency, and 500 m s pulse width) were unchanged for ﬁve
months prior to syncope. He was on levetiracetam 4000 mg/day
and topiramate 600 mg/day, with the last change in dose more
than one year prior to syncope. He had been on both AEDs for more
than 10 years. He was on stable dose of anxiolytic alprazolam
1 mg/day for one year. His seizure frequency was unchanged for
many years. Immediately before hospitalization, his sister, who
was a registered nurse, had observed heart rate in the 40 s during
his syncope, occurring every 3–4 min. Similar observation of
bradycardia on cardiac rhythm strip was seen, with VNS
stimulation felt by the patient. He had sinus bradycardia, with
heart rate of low 30 s, which instantaneously resolved when the
VNS was deactivated. When diagnostic testing was attempted, he
had immediate syncope after VNS was reactivated, associated with
sinus bradycardia and eight-second asystole. Thus, VNS was again
deactivated, without any further bradycardia or syncope. His
comprehensive metabolic panel was normal. X-ray ruled out lead
breakage. Cardiologist had recommended placement of temporary
transvenous pacemaker backup when testing the integrity of the
VNS and its effect on cardiac conduction system and blood
pressure, but the patient and his family chose to leave the VNS
deactivated. One month after VNS deactivation, a 48-h Holter
monitor showed normal heart rate and rhythm. A transthoracicserved.
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concern for worsening of his convulsion, but after six months, his
seizure frequency had remained stable, without any convulsion.
3. Discussion
This case raises the concern for late-onset bradyarrhythmia
after VNS implantation. Though rarely observed in patients with
VNS, it is a serious and potentially fatal complication. In our case,
the observed syncope and bradycardia coincided with VNS
activation, every 3–4 min versus 3.2 min, respectively. Bradyar-
rhythmia and syncope instantly reappeared when the VNS was
reactivated, and never recurred when the device was again
deactivated. Cardiac and metabolic causes were ruled out. Our
patient had no prior history of cardiac problems. The role of VNS is
obscured, however. As pointed out in a preceding case, VNS is not
expected to cause efferent stimulation of the vagus nerve cardiac
ﬁbers, hence bradycardia and asystole are unusual adverse effect
[1]. Previous cases had raised possible contribution of newly added
levetiracetam for status epilepticus [2], and worsening seizure and
changes in AED [3]. In our case, VNS parameters, seizure frequency,
and AED regimen were unchanged for relatively long period of
time. Also, X-ray had ruled out lead breakage. Unfortunately, a
limitation of this report is the absence of device diagnostics, to
ensure device proper functioning. The bradyarrythmia was most
likely related to VNS, but the ultimate cause remains unclear.
Anatomic variation of vagus nerve innervation of the heart
could not be ruled out. However, this would be a more likely
explanation if symptom onset was seen earlier, during or
closely after initial device placement or generator replacement.
Alternatively, a change in either the sensitivity of cardiacmechanoreceptors or the function of nucleus tractus soltarius in
the medulla might have occurred, due to chronic vagus nerve
stimulation by the device. On the other hand, underlying new
conduction system disease seems less plausible, but could not be
ruled out.
Lastly, it is uncertain to why this case’s seizure control did not
change after VNS deactivation. It can only be hypothesized that the
continuing control may be related to a change of vagus nerve
function due to chronic nerve stimulation, any prior AED changes
made after initial VNS placement, or the natural history of his
epilepsy.
In conclusion, clinicians should be vigilant for rare bradycardia
and asystole in patients with VNS, even years after device
implantation.
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